Receipt date: 03/05/2009

PTO/SB/08a (01-09)
Approved for use through 02/28/2009, OMB 0651-0031
Retent and Trademody Office LLS DEPARTMENT OF COMMEDICAL

Ur	der the Paperwork Reduction	Act of 19	995, no persons are required to re		mation unless it contains a valid OMB control numb	
Su	bstitute for form 1449/PTO			Complete if Known		
				Application Number	10/706,100-Conf. #7710	
11	VEORMATION	1 DI	SCLOSURE	Filing Date	November 12, 2003	
5	TATEMENT B	3Y /	APPLICANT	First Named Inventor	Seymour Fein	
				Art Unit	1654	
	(Use as many sh	eets as	s necessary)	Examiner Name	A. D. Kosar	
Sheet	1	of	2	Attorney Docket Number	SER-001	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	A78*	US-20090005432	01-01-2009	Fein		
	A79*	US-20090042970	02-12-2009	Herschkowitz et al.		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ⁵ -Number ⁵ -Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁰		
	B8	WO-09/021007	02-12-2009	SERENITY PHARMACEUTICALS CORP				
						П		
						П		

Examiner	Date
Signature	Considered

"EXAMINED Initial Industrian considered, whether or not clusten is a conference with MIFE 960. Date lies brough cluster in not no conformate and reconsidered broked copy of the form when not communication to applicant." CITE 100, These applications will be made to the CIE which are independent of not to the CIE No. are not supplied (under 37 CFFT 158(q))(2)(q)) because that application was filled after June 30, 2000 of a multiple in the Property of the CIE o

Receipt date: 03/05/2009

PTOSE080 to 1-09
Approved for use through 0228/2005 0/180 501-001
U.S. Patient all Talebrank Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless à contains a valid 0/180 centrel number

Sub	estitute for form 1449/PTO			Complete if Known	
Cooling of the Property of				Application Number	10/706,100-Conf. #7710
l IN	VECKMATION	I DI	SCLOSURE	Filing Date	November 12, 2003
l s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Seymour Fein
				Art Unit	1654
	(Use as many sh	eets a	s necessary)	Examiner Name	A. D. Kosar
Sheet	2	of	2	Attorney Docket Number	SER-001

		NON PATENT LITERATURE DOCUMENTS	
Examiņer Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
	C15	Agnoli et al. (2002) "Low-dose desmopressin infusion: renal action in healthy women in moderate salt retention and depletion, and interactions with prostanoids," Prostaglandins Leukotrienes and Essential Fatty Acids 67(4): 263-273.	
	C16	Grossman et al. (1980) "Two New Modes of Desmopressin (DDAVP) Administration," British Medical Journal 280(6225): 1215.	
	C17	Janknegt et al. (1997) "Oral Desmopressin as a New Treatment Modality for Primary Nocturnal Enuresis in Adolescents and Adults: A Double-Blind, Randomized, Multicenter Study," Journal of Urology 157(2): 513-517	
	C18	Robinson (1976) "DDAVP in the Treatment of Central Diabetes Insipidus," N Engl J Med 294: 507-511	
	C19	Supplementary European Search Report (2008) for European Application No. EP03781836 (4 pages).	
	C20	Swain (1999) "Blister Packaging Leads the Way: Despite continous pressure to contain costs, the demand for pharmaceutical packages keeps growing," Pharma and Medical Packaging News Magazine (4 pages)	
			=
			Н

Examiner Signature	/Andrew D. Kosar/	Date Considered	02/05/2010

^{*}EXAM/NER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.